ultra-long-acting insulin

Ultra-long-acting insulin (internally designated as CA106) is a biologic insulin analog being developed by Chongqing Chenan Biological Pharmaceutical, a subsidiary of Zhifei Biological Products, for the treatment of diabetes mellitus. It functions as an insulin receptor agonist designed to provide a significantly extended duration of action compared to standard long-acting insulins like glargine or degludec. The molecule is engineered to maintain stable basal insulin levels over a prolonged period, potentially allowing for once-weekly subcutaneous administration. This asset is a key component of Chenan Bio's metabolic pipeline, which aims to improve patient compliance and glycemic control through advanced protein engineering.

Other names

超长效胰岛素